Mylan Vice Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Opening BellPITTSBURGH,
Feb. 19 /PRNewswire-FirstCall/ --
Mylan Inc. (Nasdaq: MYL)
today announced that its Vice Chairman and CEO
Robert J. Coury will preside
over the NASDAQ Stock Market opening on
Friday, Feb. 20 from
9:15 to 9:30 a.m.
ET. Coury will ring the opening bell to celebrate the company's switch from
The New York Stock Exchange (NYSE) to NASDAQ.
Mylan's common stock began trading on NASDAQ Dec. 29, 2008. The company is
listed on the NASDAQ Global Select Market, and its common stock continues to
trade under the "MYL" ticker symbol. Mylan's mandatory convertible preferred
stock and 1.25% convertible notes also moved to NASDAQ with the ticker symbols
"MYLNP" and "MYLNG," respectively.
Feed Information - The Opening Bell is available from 9:20 to 9:35 a.m. on
Galaxy 19 C/15, downlink frequency 4000 vertical. The feed can also be found
on Ascent fiber 1623. Technical questions should be directed to Jolene
Libretto at 646-441-5220.
Radio Feed - An audio transmission of the Opening Bell is also available
from 9:20 to 9:35 a.m. on uplink IA6 C band / transponder 24, downlink
frequency 4180 horizontal. The feed can be found on Ascent fiber 1623 as well.
Webcast - A live webcast of the NASDAQ Opening Bell will be available at:
http://www.nasdaq.com/reference/marketsite_about.stm.
Photos - To obtain a hi-resolution photograph of the Market Open, please
go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the
market open of your choice.
About Mylan
Mylan Inc., which provides products to customers in more than 140
countries and territories, ranks among the leading diversified generic and
specialty pharmaceutical companies in the world. The company maintains one of
the industry's broadest -- and highest quality -- product portfolios,
supported by a robust product pipeline; owns a controlling interest in the
world's third largest active pharmaceutical ingredient manufacturer; and
operates a specialty business focused on respiratory and allergy therapies.
For more information, please visit www.mylan.com.
SOURCE Mylan Inc.
-0- 02/19/2009
/CONTACT: Michael Laffin of Mylan Inc., +1-724-514-1968, or NASDAQ,
Jolene Libretto, +1-646-441-5220/
/Web Site: http://www.mylan.com /
(MYL MYLNG MYLNP)
CO: Mylan Inc.
ST: Pennsylvania
IN: MTC HEA
SU: CCA
PR
-- NE72904 --
8004 02/19/2009 10:00 EST http://www.prnewswire.com